{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:28:21Z","timestamp":1786512501033,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Monoclonal gammopathy of undetermined significance (MGUS) is a common premalignant condition typically associated with progression to plasma cell disorders. Research suggests that MGUS may also coexist with or precede other lymphoid malignancies, potentially reflecting shared mechanisms involving chronic immune dysregulation. We report a 73-year-old man with more than 10 years of long-standing polyclonal immunoglobulin elevation, who subsequently developed IgA-\u03bb MGUS and was later diagnosed with primary colonic diffuse large B-cell lymphoma (DLBCL). Molecular analysis identified mutations in\n                    <jats:italic>TET2<\/jats:italic>\n                    ,\n                    <jats:italic>IDH2<\/jats:italic>\n                    ,\n                    <jats:italic>IGLL5<\/jats:italic>\n                    , and\n                    <jats:italic>DUSP2<\/jats:italic>\n                    . Rather than indicating a direct clonal transformation, this case may reflect a multistep process involving chronic immune dysregulation and independent or parallel B-cell clonal events. These findings highlight the potential clinical significance of long-standing immunoglobulin abnormalities and suggest the potential value of longitudinal immune and molecular monitoring.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1878363","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:43:53Z","timestamp":1786509833000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: longitudinal immunoglobulin abnormalities preceding IgA-\u03bb MGUS and colonic DLBCL: a case suggesting immune-driven B-cell dysregulation"],"prefix":"10.3389","volume":"16","author":[{"given":"Huifeng","family":"Qian","sequence":"first","affiliation":[{"name":"Shaoxing Second Hospital","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dong","sequence":"additional","affiliation":[{"name":"Shaoxing Second Hospital","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanqiao","family":"Shen","sequence":"additional","affiliation":[{"name":"Shaoxing Second Hospital","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01658-y","article-title":"Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma","volume":"18","author":"Chowdhury","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000038013","article-title":"Primary colon lymphomas: An analysis of our experience over the last 18 years","volume":"103","author":"Hasturk","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101242","article-title":"From MGUS to multiple myeloma: Unraveling the unknown of precursor states","volume":"68","author":"Hevroni","year":"2024","journal-title":"Blood Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000850696.86402.84","article-title":"A meta-analysis of the rate of Malignant progression of monoclonal gammopathy of undetermined significance: preliminary findings from a systematic review","volume":"6","author":"Quinn","year":"2022","journal-title":"HemaSphere"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4317\u2013","DOI":"10.1182\/blood-2021-147712","article-title":"Common gene expression signature of B-cells of Waldenstr\u00f6m macroglobulinemia (WM) and IgM monoclonal gammopathies of undetermined significance (IgM MGUS) compared to healthy subjects","volume":"138","author":"Trojani","year":"2021","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12254-020-00630-z","article-title":"Monoclonal gammopathy of undetermined significance (MGUS): where is the hidden danger? Definition and work-up","volume":"14","author":"Jeryczynski","year":"2020","journal-title":"memo - Magazine Eur Med Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"876271","DOI":"10.3389\/fimmu.2022.876271","article-title":"Autoimmunity, infections, and the risk of monoclonal gammopathy of undetermined significance","volume":"13","author":"Sigurbergsd\u00f3ttir","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-024-01374-y","article-title":"Genomic instability and genetic heterogeneity in aging: Insights from clonal hematopoiesis (CHIP), monoclonal gammopathy (MGUS), and monoclonal B-cell lymphocytosis (MBL)","volume":"47","author":"Kallai","year":"2025","journal-title":"Geroscience"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-026-01119-0","article-title":"Diagnosis, risk stratification and management of smouldering multiple myeloma","volume":"23","author":"Zanwar","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.7061","article-title":"Efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B-cell lymphoma: A real-world, multi-center, retrospective cohort study","volume":"43","author":"Zhao","year":"2025","journal-title":"Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1825-y","article-title":"IgA monoclonal gammopathy accompanying extranodal B cell lymphomas","volume":"93","author":"Boting","year":"2014","journal-title":"Ann Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184440","article-title":"Serum paraprotein is associated with adverse prognostic factors and outcome, across different subtypes of mature B-cell Malignancies-a systematic review","volume":"15","author":"Cox","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0520","article-title":"Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: Implications for recategorizing disease entities in the presence of evolving scientific evidence","volume":"85","author":"Rajkumar","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.12.001","article-title":"Activation of thyroid antigen-reactive B cells in recent onset autoimmune thyroid disease patients","volume":"89","author":"Smith","year":"2018","journal-title":"J Autoimmun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.11613\/bm.2010.012","article-title":"Increased IgA in a subject with positive anti-thyroid autoantibodies - a case report","volume":"20","author":"Dodig","year":"2010","journal-title":"Biochem Med (Zagreb)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.8124","article-title":"Diagnosis and management of monoclonal gammopathy of undetermined significance: A review","volume":"185","author":"Liu","year":"2025","journal-title":"JAMA Intern Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5650\u2013","DOI":"10.1182\/blood.v128.22.5650.5650","article-title":"Risk of progression in monoclonal gammopathy of undetermined significance (MGUS): Results from a population-based screening study","volume":"128","author":"Lindqvist","year":"2016","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1404298","DOI":"10.3389\/fonc.2024.1404298","article-title":"Primary intestinal diffuse large B-cell lymphoma: novel insights and clinical perception","volume":"14","author":"Chen","year":"2024","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101341","DOI":"10.1016\/j.blre.2025.101341","article-title":"The microbiome-lymphoma Axis: A systematic review and Meta-analysis of gut Dysbiosis pattern in diffuse large B-cell lymphoma","volume":"75","author":"Elkourashy","year":"2026","journal-title":"Blood Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204606","article-title":"Pathogenesis and clinical relevance of diffuse large B-cell lymphoma proteogenotypes","volume":"144","author":"Enssle","year":"2024","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-0657","article-title":"TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes B-cell lymphomagenesis","volume":"8","author":"Dominguez","year":"2018","journal-title":"Cancer Discov"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70393","article-title":"Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial","volume":"10","author":"Maher","year":"2026","journal-title":"HemaSphere"},{"key":"B24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/path.6446","article-title":"Analysis of IDH1 and IDH2 mutations as causes of the hypermethylator phenotype in colorectal cancer","volume":"267","author":"Ward","year":"2025","journal-title":"J Pathol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41408-025-01304-x","article-title":"Disease characteristics and monitoring of IDH1\/IDH2-mutated acute myeloid leukemia","volume":"15","author":"Dantec","year":"2025","journal-title":"Blood Cancer J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40164-022-00325-7","article-title":"Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma","volume":"11","author":"Li","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.5483\/bmbrep.2019.52.9.192","article-title":"Deep sequencing of B cell receptor repertoire","volume":"52","author":"Kim","year":"2019","journal-title":"BMB Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12659","article-title":"Immunoglobulin gene analysis as a tool for investigating human immune responses","volume":"284","author":"Dunn-Walters","year":"2018","journal-title":"Immunol Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(20)30222-2","article-title":"A perspective on improving the R-CHOP regimen: From Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise","volume":"7","author":"Lue","year":"2020","journal-title":"Lancet Haematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2759\u2013","DOI":"10.1182\/blood-2025-2759","article-title":"Real-world comparative outcomes of pola-R-CHP versus R-CHOP in patients with diffuse large B-cell lymphoma","volume":"146","author":"Thor","year":"2025","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1878363\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:44:18Z","timestamp":1786509858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1878363\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1878363"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1878363","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1878363"}}